Plus   Neg

5 Top Losers In Healthcare Sector (CHFS, ONTX, DRAD…)

pharmadown sept16 lt

The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

1. CHF Solutions Inc. (CHFS)

CHF Solutions is a medical device company focused on commercializing Aquadex FlexFlow system for aquapheresis therapy.

Aquadex FlexFlow system is indicated for ultrafiltration to reduce fluid overload in patients when diuretics fail. The device is FDA 510(k) market cleared and CE marked.

Lost 16.09% to close Monday's trading at $2.19.

News: No news

Recent event:

On August 2, 2019, the Company announced financial results for the second quarter ended June 30, 2019.

Net loss for the second quarter of 2019 was $4.43 million or $1.93 per share compared to a net loss of $4.18 million or $13.03 per share in the year-ago quarter. Revenue for the recent second quarter was $1.7 million compared to $1.1 million in the year-earlier quarter.

The Company ended June 30, 2019, with cash of $7.40 million.

2. Onconova Therapeutics Inc. (ONTX)

Onconova is a late-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer.

Lost 15% to close Monday's trading at $2.12.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase III pivotal trial with intravenous Rigosertib for high-risk second-line patients with Myelodysplastic Syndromes, dubbed INSPIRE, is underway. Enrollment in the trial is expected to be completed by the end of 2019, with top-line data anticipated in the first half of 2020 following full enrollment and 288 death events.
-- In December 2018, Onconova applied to the FDA for a Special Protocol Assessment (SPA) for a phase III trial of oral Rigosertib in combination with Azacitidine for treatment of first-line higher-risk Myelodysplastic syndrome patients. The Company expects completion of the FDA's SPA decision before the end of 2019.

Upcoming Event:

On September 19, 2019, the Company will make a presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit.

3. IRIDEX Corp. (IRIX)

IRIDEX Corp. is a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases.

Lost 11.89% to close Monday's trading at $2.00.

News: No news

Recent event:

On August 6, 2019, the Company reported financial results for the second quarter ended June 29, 2019.

Revenue for the three months ended June 29, 2019, increased 1.2% to $10.4 million compared to $10.3 million during the same period of the prior year. For the full year 2019, the Company expects revenue to range between $41 million and $44 million. Revenue for the year ended December 29, 2018, was $42.6 million.

4. OpGen Inc. (OPGN)

OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease.

Lost 11.37% to close Monday's trading at $7.09.

News: No news

Recent event:

On September 4, 2019, OpGen and Curetis N.V., a developer of next-level molecular diagnostic solutions, have entered into a definitive agreement to combine their businesses, subject to approval by both companies' respective shareholders and Curetis' debt financing providers.

5. Digirad Corp. (DRAD)

Digirad designs, manufactures, and distributes diagnostic medical imaging products.
Lost 11.33% to close Monday's trading at $5.01.

News: The Company announced preliminary guidance for 2020.

For FY 2020, Digirad expects revenue to be in the range of $130 million to $150 million. Total revenues from continuing operations in the first half ended June 30, 2019, were $49.7 million, and total revenue for the twelve months ended December 31, 2018, was $104.2 million.

Recent Event:

On September 10, 2019, the Company announced that it completed the acquisition of ATRM Holdings, Inc. The merger is part of the transformation of Digirad into a diversified holding company.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT